Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016
- PMID: 29762765
- PMCID: PMC6192504
- DOI: 10.1093/schbul/sby058
Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016
Abstract
Introduction: The global burden of disease (GBD) studies have derived detailed and comparable epidemiological and burden of disease estimates for schizophrenia. We report GBD 2016 estimates of schizophrenia prevalence and burden of disease with disaggregation by age, sex, year, and for all countries.
Method: We conducted a systematic review to identify studies reporting the prevalence, incidence, remission, and/or excess mortality associated with schizophrenia. Reported estimates which met our inclusion criteria were entered into a Bayesian meta-regression tool used in GBD 2016 to derive prevalence for 20 age groups, 7 super-regions, 21 regions, and 195 countries and territories. Burden of disease estimates were derived for acute and residual states of schizophrenia by multiplying the age-, sex-, year-, and location-specific prevalence by 2 disability weights representative of the disability experienced during these states.
Findings: The systematic review found a total of 129 individual data sources. The global age-standardized point prevalence of schizophrenia in 2016 was estimated to be 0.28% (95% uncertainty interval [UI]: 0.24-0.31). No sex differences were observed in prevalence. Age-standardized point prevalence rates did not vary widely across countries or regions. Globally, prevalent cases rose from 13.1 (95% UI: 11.6-14.8) million in 1990 to 20.9 (95% UI: 18.5-23.4) million cases in 2016. Schizophrenia contributes 13.4 (95% UI: 9.9-16.7) million years of life lived with disability to burden of disease globally.
Conclusion: Although schizophrenia is a low prevalence disorder, the burden of disease is substantial. Our modeling suggests that significant population growth and aging has led to a large and increasing disease burden attributable to schizophrenia, particularly for middle income countries.
Figures





Similar articles
-
Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017.Arthritis Rheumatol. 2020 Nov;72(11):1916-1927. doi: 10.1002/art.41404. Epub 2020 Sep 10. Arthritis Rheumatol. 2020. PMID: 32755051
-
Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet Psychiatry. 2022 Feb;9(2):137-150. doi: 10.1016/S2215-0366(21)00395-3. Epub 2022 Jan 10. Lancet Psychiatry. 2022. PMID: 35026139 Free PMC article.
-
Global incidence, prevalence, and disability of vertebral fractures: a systematic analysis of the global burden of disease study 2019.Spine J. 2022 May;22(5):857-868. doi: 10.1016/j.spinee.2021.12.007. Epub 2021 Dec 11. Spine J. 2022. PMID: 34906740
-
The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet Gastroenterol Hepatol. 2020 Jun;5(6):561-581. doi: 10.1016/S2468-1253(19)30408-X. Epub 2020 Mar 13. Lancet Gastroenterol Hepatol. 2020. PMID: 32178772 Free PMC article.
-
The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study.PLoS One. 2013 Oct 24;8(10):e76635. doi: 10.1371/journal.pone.0076635. eCollection 2013. PLoS One. 2013. PMID: 24204649 Free PMC article. Review.
Cited by
-
Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia.Neuropsychiatr Dis Treat. 2021 Apr 30;17:1289-1297. doi: 10.2147/NDT.S305200. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 33958870 Free PMC article.
-
Traumatic events and psychotic experiences: a nationally representative study in Thailand.Epidemiol Psychiatr Sci. 2021 Jun 8;30:e47. doi: 10.1017/S2045796021000172. Epidemiol Psychiatr Sci. 2021. PMID: 34100345 Free PMC article.
-
A glimpse of gender differences in schizophrenia.Gen Psychiatr. 2022 Aug 30;35(4):e100823. doi: 10.1136/gpsych-2022-100823. eCollection 2022. Gen Psychiatr. 2022. PMID: 36118418 Free PMC article. No abstract available.
-
Glutamatergic dysfunction in Schizophrenia.Transl Psychiatry. 2022 Dec 3;12(1):500. doi: 10.1038/s41398-022-02253-w. Transl Psychiatry. 2022. PMID: 36463316 Free PMC article. Review.
-
Awareness, utilization and influencing factors of social supports for main informal caregivers of schizophrenia patients: a cross-sectional study in primary care settings in Beijing, China.BMC Fam Pract. 2020 Sep 17;21(1):192. doi: 10.1186/s12875-020-01257-z. BMC Fam Pract. 2020. PMID: 32943006 Free PMC article.
References
-
- Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–448. - PubMed
-
- Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?Arch Gen Psychiatry. 2007;64:1123–1131. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous